Understanding and Potential Applications of DEFB109A (G245912)

Target Name: DEFB109A

NCBI ID: G245912

DEFB109A

Other Name(s): Defensin beta 109A (pseudogene) | defensin beta 109A (pseudogene) | DEFB109 | DEFB109P1 | DEFB-9

Understanding and Potential Applications of DEFB109A

Defensin beta 109A (DEFB109A) is a protein that is expressed in various cell types of the human body, including epithelial, hematopoietic, and nervous cells. It is a 21-kDa protein that consists of 154 amino acid residues. DEFB109A plays a critical role in the cell's defense mechanism, and it is involved in the regulation of various cellular processes, including cell signaling, cell adhesion, and inflammation.

The drug target (or biomarker) potential of DEFB109A makes it an attractive subject of research, and various studies have investigated its potential as a drug target or biomarker. In this article, we will discuss the current understanding of DEFB109A, its potential drug target status, and its potential clinical applications.

Current Understanding of DEFB109A

DEFB109A is a cytoplasmic protein that is involved in the regulation of various cellular processes. It is a member of the Defensin family, which includes several structurally similar proteins that play a critical role in the regulation of cellular processes, including cell signaling, cell adhesion, and inflammation.

The Defensin family proteins are involved in the regulation of cellular processes that are essential for the survival and proper functioning of cells. They do this by interacting with various signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

DEFB109A is involved in several cellular processes, including cell adhesion, migration, and the regulation of cell signaling pathways. It is a critical regulator of the TGF-β pathway, which is involved in cell signaling, cell adhesion, and tissue regeneration.

In addition to its role in the TGF-β pathway, DEFB109A is also involved in the regulation of cell signaling pathways that are essential for the survival and proper functioning of cells. It plays a critical role in the regulation of the PI3K/Akt pathway, which is involved in cell signaling, cell adhesion, and the regulation of cellular processes that are essential for the survival and proper functioning of cells.

DEFB109A is also involved in the regulation of several cellular processes that are essential for the survival and proper functioning of cells. It plays a critical role in the regulation of the NF-kappa-B pathway, which is involved in inflammation, cell signaling, and the regulation of cellular processes that are essential for the survival and proper functioning of cells.

Potential Drug Target or Biomarker

The potential drug target or biomarker status of DEFB109A makes it an attractive subject of research. DEFB109A is a cytoplasmic protein that is expressed in various cell types of the human body, including epithelial, hematopoietic, and nervous cells. It is a 21-kDa protein that consists of 154 amino acid residues.

The potential drug target status of DEFB109A makes it an attractive subject of research. It is involved in several cellular processes that are essential for the survival and proper functioning of cells, including cell signaling, cell adhesion, and the regulation of inflammation.

There are several potential strategies that could be used to target DEFB109A as a drug or biomarker. One strategy is to use small molecules or antibodies that specifically interact with DEFB109A to inhibit its function. Another strategy is to use small molecules or antibodies that specifically interact with DEFB109A to

Protein Name: Defensin Beta 109A (pseudogene)

The "DEFB109A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB109A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets